glp 1/gip agonist Tirzepatide's Unique Mechanism of Action Main physiological actions of the
Description
It is administered by subcutaneous injection once a week , can reduce the dosage and frequency of medication for patients
Results from Phase 2 trials were subsequently halted due to excessive rates of gastrointestinal adverse events leading to participant withdrawals
Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases
This supports a healthy weight loss
This flattens postprandial glucose spikes and help control blood sugar
Neuroscience Letters
